Cardiac risk in the treatment of breast cancer: assessment and management
2015 (English)In: Breast Cancer: Targets and Therapy, ISSN 1179-1314, E-ISSN 1179-1314, Vol. 7, 21-35 p.Article, review/survey (Refereed) PublishedText
As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be clarified and are the subjects of extensive ongoing clinical research. This review summarizes the incidence of cardiac toxicity due to breast cancer adjuvant therapy and highlights the current trends in early detection and management of cardiac toxicities.
Place, publisher, year, edition, pages
2015. Vol. 7, 21-35 p.
adjuvant, anthracyclines, cardiac toxicity, radiotherapy, trastuzumab
Cancer and Oncology Cardiac and Cardiovascular Systems
IdentifiersURN: urn:nbn:se:uu:diva-276111DOI: 10.2147/BCTT.S47227ISI: 000366124300001PubMedID: 25653554OAI: oai:DiVA.org:uu-276111DiVA: diva2:901902